Ken Hatogai

855 total citations
36 papers, 546 citations indexed

About

Ken Hatogai is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Ken Hatogai has authored 36 papers receiving a total of 546 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pulmonary and Respiratory Medicine, 19 papers in Surgery and 19 papers in Oncology. Recurrent topics in Ken Hatogai's work include Cancer Immunotherapy and Biomarkers (14 papers), Esophageal Cancer Research and Treatment (13 papers) and Gastric Cancer Management and Outcomes (10 papers). Ken Hatogai is often cited by papers focused on Cancer Immunotherapy and Biomarkers (14 papers), Esophageal Cancer Research and Treatment (13 papers) and Gastric Cancer Management and Outcomes (10 papers). Ken Hatogai collaborates with scholars based in Japan, United States and France. Ken Hatogai's co-authors include Takashi Kojima, Hiroyuki Daiko, Satoshi Fujii, Tomonori Yano, Thomas F. Gajewski, Emily F. Higgs, Toshihiko Doi, Atsushi Ohtsu, Blake Flood and Yusuke Yoda and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Ken Hatogai

32 papers receiving 542 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ken Hatogai Japan	13	288	240	236	134	78	36	546
Yuta Kasagi Japan	12	258 0.9×	372 1.6×	148 0.6×	58 0.4×	137 1.8×	37	605
Justin A. Drake United States	12	130 0.5×	150 0.6×	182 0.8×	101 0.8×	66 0.8×	25	378
Xi Jiao China	13	146 0.5×	106 0.4×	254 1.1×	95 0.7×	77 1.0×	21	437
Taiyuan Li China	12	112 0.4×	335 1.4×	414 1.8×	57 0.4×	57 0.7×	42	564
Shutaro Hori Japan	12	111 0.4×	145 0.6×	295 1.3×	76 0.6×	57 0.7×	56	453
Shuisheng Zhang China	13	231 0.8×	155 0.6×	203 0.9×	30 0.2×	118 1.5×	33	525
Daichi Nomoto Japan	12	165 0.6×	239 1.0×	247 1.0×	90 0.7×	176 2.3×	24	520
Chao Lin China	15	160 0.6×	158 0.7×	256 1.1×	65 0.5×	163 2.1×	47	592
Akihito Okazaki Japan	12	245 0.9×	217 0.9×	269 1.1×	25 0.2×	53 0.7×	58	516
Guanghai Dai China	13	128 0.4×	122 0.5×	355 1.5×	60 0.4×	63 0.8×	34	448

Countries citing papers authored by Ken Hatogai

Since Specialization

Citations

This map shows the geographic impact of Ken Hatogai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ken Hatogai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ken Hatogai more than expected).

Fields of papers citing papers by Ken Hatogai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ken Hatogai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ken Hatogai. The network helps show where Ken Hatogai may publish in the future.

Co-authorship network of co-authors of Ken Hatogai

This figure shows the co-authorship network connecting the top 25 collaborators of Ken Hatogai. A scholar is included among the top collaborators of Ken Hatogai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ken Hatogai. Ken Hatogai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Finn, Richard S., Masatoshi Kudo, Ivan Borbath, et al.. (2024). Pembrolizumab (pembro) in patients (pts) with sorafenib-treated (cohort 1) and treatment (tx)-naive (cohort 2) advanced hepatocellular carcinoma (aHCC) after additional follow-up in the phase 2 KEYNOTE-224 study.. Journal of Clinical Oncology. 42(16_suppl). 4100–4100. 2 indexed citations

Kudo, Masatoshi, Ann‐Lii Cheng, Philippe Merle, et al.. (2024). Association between beta-catenin (CTNNB1) mutations and clinical outcomes of pembrolizumab in advanced hepatocellular carcinoma (aHCC): Exploratory analyses from KEYNOTE-240.. Journal of Clinical Oncology. 42(16_suppl). 4109–4109. 1 indexed citations

El-Khoueiry, Anthony B., Tae‐You Kim, Jean‐Frédéric Blanc, et al.. (2024). International, open-label phase 2 study of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitors (ICI).. Journal of Clinical Oncology. 42(16_suppl). 4007–4007. 13 indexed citations

Ziblat, Andrea, Brendan Horton, Emily F. Higgs, et al.. (2024). Batf3+ DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy. Cell Reports. 43(5). 114141–114141. 11 indexed citations

Li, Shuyin, Jason W. Shapiro, Hardik Shah, et al.. (2024). Abstract 5350: Decr2 regulates tumor cell ferroptosis and immunotherapy efficacy. Cancer Research. 84(6_Supplement). 5350–5350. 1 indexed citations

Matossian, Margarite D., Christine Y. Shiang, Ken Hatogai, et al.. (2024). High tumor glucocorticoid receptor expression in early-stage, triple-negative breast cancer is associated with increased T-regulatory cell infiltration. Breast Cancer Research and Treatment. 209(3). 563–572. 1 indexed citations

Higgs, Emily F., Riyue Bao, Ken Hatogai, & Thomas F. Gajewski. (2022). Wilms tumor reveals DNA repair gene hyperexpression is linked to lack of tumor immune infiltration. Journal for ImmunoTherapy of Cancer. 10(6). e004797–e004797. 10 indexed citations

Reschke, Robin, Jovian Yu, Blake Flood, et al.. (2021). Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma. Journal for ImmunoTherapy of Cancer. 9(9). e003521–e003521. 98 indexed citations

Labbate, Craig, Ken Hatogai, Ryan P. Werntz, et al.. (2019). Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy. Journal for ImmunoTherapy of Cancer. 7(1). 66–66. 62 indexed citations

10.

Hatogai, Ken, Satoshi Fujii, Shigehisa Kitano, et al.. (2019). Relationship between the immune microenvironment of different locations in a primary tumour and clinical outcomes of oesophageal squamous cell carcinoma. British Journal of Cancer. 122(3). 413–420. 13 indexed citations

11.

Hatogai, Ken, Nobuo Mochizuki, Masaki Tanaka, et al.. (2019). Risk factors for febrile neutropenia in neoadjuvant docetaxel, cisplatin, and 5-fluorouracil chemotherapy for esophageal cancer. Supportive Care in Cancer. 28(4). 1849–1854. 8 indexed citations

12.

Yano, Tomonori, Ken Hatogai, Takashi Kojima, et al.. (2017). Salvage endoscopic resection (ER) after chemoradiotherapy for esophageal squamous cell carcinoma: What are the risk factors for recurrence after salvage ER?. Digestive Endoscopy. 30(3). 338–346. 15 indexed citations

13.

Hatogai, Ken, Satoshi Fujii, Takashi Kojima, et al.. (2017). Large-scale comprehensive immunohistochemical biomarker analyses in esophageal squamous cell carcinoma. Journal of Cancer Research and Clinical Oncology. 143(11). 2351–2361. 12 indexed citations

14.

Hatogai, Ken, Satoshi Fujii, Takashi Kojima, et al.. (2017). Concordance between PIK3CA mutations in endoscopic biopsy and surgically resected specimens of esophageal squamous cell carcinoma. BMC Cancer. 17(1). 36–36. 5 indexed citations

15.

Hatogai, Ken, Tomonori Yano, Takashi Kojima, et al.. (2016). Local efficacy and survival outcome of salvage endoscopic therapy for local recurrent lesions after definitive chemoradiotherapy for esophageal cancer. Radiation Oncology. 11(1). 31–31. 23 indexed citations

16.

Hatogai, Ken & Toshihiko Doi. (2016). [Molecular Subtypes of Gastric Cancer].. PubMed. 43(3). 281–5.

17.

Hatogai, Ken, Tomonori Yano, Takashi Kojima, et al.. (2015). Salvage photodynamic therapy for local failure after chemoradiotherapy for esophageal squamous cell carcinoma. Gastrointestinal Endoscopy. 83(6). 1130–1139.e3. 36 indexed citations

18.

Hatogai, Ken. (2013). Unexpected endoscopic full-thickness resection of a duodenal neuroendocrine tumor. World Journal of Gastroenterology. 19(26). 4267–4267. 5 indexed citations

19.

Mizuki, Akira, Masayuki Tatemichi, Ken Hatogai, et al.. (2013). [Timely colonoscopy leads to faster identification of bleeding diverticulum].. PubMed. 110(11). 1927–33. 7 indexed citations

20.

Hatogai, Ken, Naoki Hosoe, Hiroyuki Imaeda, et al.. (2012). Role of Enhanced Visibility in Evaluating Polyposis Syndromes Using a Newly Developed Contrast Image Capsule Endoscope. Gut and Liver. 6(2). 218–222. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact